12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a.

      Biochemical and Biophysical Research Communications
      Animals, Cardiomegaly, metabolism, pathology, Cell Line, Hydrogen Sulfide, Hypertrophy, MicroRNAs, biosynthesis, genetics, Myocytes, Cardiac, drug effects, Natriuretic Peptide, Brain, RNA, Messenger, Rats, Reactive Oxygen Species, Sulfides, pharmacology, Up-Regulation

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hydrogen sulphide (H(2)S) has been shown to play a crucial role in cardiovascular physiology and disease. However, there is no information about the possible role of H(2)S in cardiomyocyte hypertrophy (CH). Our results showed that pretreatment with NaHS, an H(2)S donor, significantly reduced [(3)H]-leucine incorporation, cell surface area, mRNA expression of brain natriuretic peptide (BNP), intracellular reactive oxygen species (ROS), miR-21 and increased atrial natriuretic peptide (ANP) and miR-133a expression in hypertrophic cardiomyocytes. Anti-miR133a inhibitor transfection partly reduced the anti-hypertrophic effect of NaHS. In conclusion, H(2)S is a direct inhibitor of CH; it acts by increasing miR-133a and inhibiting the increase in intracellular ROS. Copyright © 2011 Elsevier Inc. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article